RecruitingPhase 2ACTRN12625000131459

Does treatment with naltrexone (a medication) improve quality of life in patients with hypothyroidism (underactive thyroid)?

ThyroLDN: a phase 2, double blind, randomised controlled trial of low dose naltrexone on thyroid-specific quality of life in Hashimoto’s thyroiditis patients with residual hypothyroid symptoms despite optimal thyroid hormone replacement.


Sponsor

St. Vincent's Hospital, Sydney

Enrollment

150 participants

Start Date

Sep 1, 2025

Study Type

Interventional

Conditions

Summary

Many people with hypothyroidism do not feel well, even when their blood tests say their thyroid levels are normal. Apart from thyroxine, there are no other approved medications available to treat hypothyroidism. Naltrexone, a medication typically used to treat other conditions, may help people with hypothyroidism feel better when taken at a low dose. The purpose of this study is to determine whether naltrexone is beneficial when used in addition to thyroxine for the treatment of hypothyroidism. Our proposed study will test if naltrexone improves quality of life and other health related measures versus a placebo tablet. This will help us to understand whether this medication (naltrexone) should be studied further as a potential treatment for hypothyroidism. Medications must be approved for use by the Australian Federal Government. Naltrexone is currently approved in Australia to treat alcohol and opioid dependence. However, it is not approved to treat hypothyroidism. Therefore, it is an experimental medication for treatment of hypothyroidism secondary to Hashimoto’s thyroiditis. This means that it must be tested to see if it is effective for this indication.


Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Inclusion Criteria7

  • Age greater of equal to 18-years.
  • Greater than 3 months since diagnosis of Hashimoto’s disease.
  • Stable thyroxine dose for greater or equal to 3 months.
  • Thyroid stimulating hormone (TSH) level within normal range.
  • Dissatisfaction with thyroxine treatment.
  • Patient-perceived residual hypothyroid symptoms.
  • Ability to provide written informed consent and adhere to the study protocol.

Exclusion Criteria4

  • Documented allergy to naltrexone.
  • Opioid dependence or inability to abstain from opioids during the study.
  • Recent modification (within 3-months) of diet, lifestyle or medication known to impact weight, blood pressure, thyroid function or other important study outcome measures.
  • Pregnancy or planning pregnancy.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Naltrexone 4.5 mg oral capsule daily for 6-months. Adherence will be assessed by drug tablet return

Naltrexone 4.5 mg oral capsule daily for 6-months. Adherence will be assessed by drug tablet return


Locations(1)

NSW, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12625000131459


Related Trials